RU2018132044A - Антитела против тау - Google Patents

Антитела против тау Download PDF

Info

Publication number
RU2018132044A
RU2018132044A RU2018132044A RU2018132044A RU2018132044A RU 2018132044 A RU2018132044 A RU 2018132044A RU 2018132044 A RU2018132044 A RU 2018132044A RU 2018132044 A RU2018132044 A RU 2018132044A RU 2018132044 A RU2018132044 A RU 2018132044A
Authority
RU
Russia
Prior art keywords
seq
antibodies against
against tau
tau
epitope
Prior art date
Application number
RU2018132044A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид ХОЛЬТЦМАН
Хун ЦЗЯН
Марк ДАЙМОНД
Найла КФОУРИ
Брендон ХОЛМС
Original Assignee
Вашингтон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вашингтон Юниверсити filed Critical Вашингтон Юниверсити
Publication of RU2018132044A publication Critical patent/RU2018132044A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
RU2018132044A 2012-07-03 2013-07-03 Антитела против тау RU2018132044A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US61/667,515 2012-07-03
US201261694989P 2012-08-30 2012-08-30
US61/694,989 2012-08-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015103228A Division RU2668159C2 (ru) 2012-07-03 2013-07-03 Антитела против тау

Publications (1)

Publication Number Publication Date
RU2018132044A true RU2018132044A (ru) 2018-10-19

Family

ID=49882495

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018132044A RU2018132044A (ru) 2012-07-03 2013-07-03 Антитела против тау
RU2015103228A RU2668159C2 (ru) 2012-07-03 2013-07-03 Антитела против тау

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015103228A RU2668159C2 (ru) 2012-07-03 2013-07-03 Антитела против тау

Country Status (17)

Country Link
US (2) US9834596B2 (cg-RX-API-DMAC7.html)
EP (2) EP3838921A3 (cg-RX-API-DMAC7.html)
JP (3) JP6345655B2 (cg-RX-API-DMAC7.html)
KR (3) KR20200013072A (cg-RX-API-DMAC7.html)
CN (2) CN108623682A (cg-RX-API-DMAC7.html)
AU (3) AU2013286680B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014033116B1 (cg-RX-API-DMAC7.html)
CA (1) CA2877397A1 (cg-RX-API-DMAC7.html)
HK (1) HK1209768A1 (cg-RX-API-DMAC7.html)
IL (3) IL236409B (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00007A (cg-RX-API-DMAC7.html)
MX (2) MX359555B (cg-RX-API-DMAC7.html)
MY (1) MY171473A (cg-RX-API-DMAC7.html)
NZ (2) NZ703423A (cg-RX-API-DMAC7.html)
RU (2) RU2018132044A (cg-RX-API-DMAC7.html)
SG (3) SG10201708959WA (cg-RX-API-DMAC7.html)
WO (1) WO2014008404A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359555B (es) 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
EP3685854A1 (en) 2012-08-16 2020-07-29 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CU24446B1 (es) * 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA2952745A1 (en) * 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6679582B2 (ja) 2014-09-30 2020-04-15 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウの動態測定
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
EA037092B1 (ru) * 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
JP6937289B2 (ja) 2015-07-06 2021-09-22 ユーシービー バイオファルマ エスアールエル Ｔａｕ結合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017027691A1 (en) * 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CN109580954B (zh) * 2015-09-16 2022-03-22 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
BR112018072394A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
HUE053679T2 (hu) 2016-07-12 2021-07-28 H Lundbeck As Hiperfoszforilezett TAU-ra specifikus antitestek és eljárások ezek alkalmazására
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
MX2019005594A (es) 2016-11-15 2019-07-04 H Lundbeck As Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MY198942A (en) 2016-12-07 2023-10-03 Genentech Inc Anti-tau antibodies and methods of use
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
ES3008133T3 (en) 2016-12-16 2025-03-21 H Lundbeck As Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CA3055957A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
TWI853617B (zh) * 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
EP3784687A1 (en) * 2018-04-27 2021-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) A method for preparing phfs-like tau aggregates
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN113631700B (zh) * 2019-03-18 2025-07-18 瑞泽恩制药公司 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
ES2969026T3 (es) * 2019-03-18 2024-05-16 Regeneron Pharma Plataforma de detección de abandonos CRISPR/CAS para revelar vulnerabilidades genéticas asociadas con la agregación de tau
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
JP7595061B2 (ja) * 2019-07-15 2024-12-05 アデル，インコーポレーテッド 抗タウ抗体およびその使用
EP4013772A4 (en) * 2019-08-13 2024-06-05 Washington University METHODS FOR DETECTING MTBR-TAU ISOFORMS AND THEIR USE
IL292130A (en) 2019-10-09 2022-06-01 Bluerock Therapeutics Lp Cells with sustained transgene expression
MX2022006676A (es) * 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
EP4241088A1 (en) * 2020-11-09 2023-09-13 Meso Scale Technologies, LLC Methods and kits for detecting tau
EP4271708A1 (en) 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies
EP4314048A1 (en) 2021-03-26 2024-02-07 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
TW202304990A (zh) 2021-03-26 2023-02-01 美商健生生物科技公司 針對成對螺旋絲ｔａｕ之人源化抗體及其用途
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
IL318722A (en) * 2022-08-23 2025-03-01 Washington University St Louis Anti-tau MTBR antibodies and methods for detecting cleaved tau fragments and uses thereof
WO2025018933A1 (en) * 2023-07-20 2025-01-23 Montoliu Gaya Laia P-tau immunoassay

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK546988A (da) 1987-10-02 1989-04-03 Du Pont Immunobestemmelse og reagenssaet til anvendesle herved
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
ATE154642T1 (de) 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
DE69233723T2 (de) 1991-12-06 2009-02-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
CA2195672A1 (en) 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
ATE277353T1 (de) 1998-09-08 2004-10-15 Innogenetics Nv Tau als marker für frühe schäden des zentralen nervensystems
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP1464702A4 (en) 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd METHOD FOR PROTEIN STABILIZATION
SG165158A1 (en) 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP1521774B1 (en) 2002-07-12 2008-08-27 Axon Neuroscience Forschungs- und Entwicklungs Gmbh Truncated tau proteins
AU2003257850A1 (en) 2002-08-14 2004-03-03 Mitsubishi Kagaku Iatron, Inc. ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US8026070B2 (en) 2005-02-19 2011-09-27 Peoplebio, Inc. Differential detection of multimeric and monomeric forms of multimer-forming polypeptides
JP2009506302A (ja) 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
TWI472329B (zh) 2008-04-24 2015-02-11 必治妥美雅史谷比公司 埃坡徽素ｄ於治療包括阿茲海默症之ｔａｕ相關疾病的用途
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
WO2010056754A2 (en) * 2008-11-11 2010-05-20 The Board Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
CA2765099A1 (en) * 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
MX2012001194A (es) * 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
US8778343B2 (en) 2009-08-28 2014-07-15 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
WO2011032155A2 (en) * 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
BR112012008381A2 (pt) 2009-09-24 2017-06-13 Inserm (Institut Nat De La Santé Et De La Rech Médicale) interação fkbp52-tau como novo alvo terapêutico para tratar os distúrbios neurológicos envolvendo disfunção da tau
US20130095492A1 (en) 2010-03-05 2013-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
EP2625198B1 (en) 2010-10-07 2015-07-22 AC Immune S.A. Antibodies recognising phospho-tau
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
US8940272B2 (en) * 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
US9506051B2 (en) 2011-05-20 2016-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
AU2012311234B2 (en) 2011-09-19 2017-09-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
CN108034005B (zh) 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
WO2013063086A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
AU2012359039B2 (en) 2011-12-20 2017-08-24 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
BR112014029566A2 (pt) 2012-05-31 2017-07-25 Univ Osaka City agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
MX359555B (es) 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
EP3685854A1 (en) 2012-08-16 2020-07-29 Ipierian, Inc. Methods of treating a tauopathy
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
JP2015527369A (ja) 2012-08-21 2015-09-17 インスティテュート フォー モレキュラー メディシン， インコーポレイテッド アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法
CA2887933A1 (en) 2012-10-12 2014-04-17 Arizona Board Of Agents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014089104A1 (en) 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
SG11201504822VA (en) 2012-12-21 2015-07-30 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
CN105143258B (zh) 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Also Published As

Publication number Publication date
MY171473A (en) 2019-10-15
AU2020223765A1 (en) 2020-09-17
AU2013286680B2 (en) 2018-07-05
MX2022000026A (es) 2022-03-22
CN104781278B (zh) 2018-06-12
JP6345655B2 (ja) 2018-06-20
IL236409B (en) 2020-10-29
EP2870176A1 (en) 2015-05-13
AU2013286680A1 (en) 2015-01-22
NZ739622A (en) 2020-01-31
JP2015530971A (ja) 2015-10-29
IN2015KN00007A (cg-RX-API-DMAC7.html) 2015-07-31
MX359555B (es) 2018-10-02
KR102494798B1 (ko) 2023-02-06
SG10201708959WA (en) 2017-11-29
SG11201408626YA (en) 2015-03-30
JP2018184398A (ja) 2018-11-22
KR20200013072A (ko) 2020-02-05
RU2668159C2 (ru) 2018-09-26
RU2015103228A3 (cg-RX-API-DMAC7.html) 2018-03-05
SG10201913370PA (en) 2020-03-30
US20150183855A1 (en) 2015-07-02
IL277643A (en) 2020-11-30
NZ703423A (en) 2018-02-23
CN108623682A (zh) 2018-10-09
HK1209768A1 (en) 2016-04-08
CA2877397A1 (en) 2014-01-09
US9834596B2 (en) 2017-12-05
BR112014033116B1 (pt) 2021-12-21
MX2014016024A (es) 2015-04-13
CN104781278A (zh) 2015-07-15
KR20200134339A (ko) 2020-12-01
BR112014033116A2 (pt) 2018-03-06
JP2020125310A (ja) 2020-08-20
EP3838921A3 (en) 2021-09-01
EP3838921A2 (en) 2021-06-23
EP2870176A4 (en) 2016-09-28
AU2018229564A1 (en) 2018-10-04
KR20150036346A (ko) 2015-04-07
WO2014008404A1 (en) 2014-01-09
RU2015103228A (ru) 2016-08-20
US20180037641A1 (en) 2018-02-08
IL236409A0 (en) 2015-02-26
IL289241A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
RU2018132044A (ru) Антитела против тау
JP2014518898A5 (cg-RX-API-DMAC7.html)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EP4356927A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201790359A1 (ru) Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами
UA111818C2 (uk) Антитіло проти csf-1r
MY198942A (en) Anti-tau antibodies and methods of use
WO2013059885A3 (en) Polypeptide constructs and uses thereof
JP2013539454A5 (cg-RX-API-DMAC7.html)
CA2872308A1 (en) Novel ha binding agents
WO2010129895A3 (en) Cd133 epitopes
NZ630847A (en) Anti-sema4d antibodies and epitopes
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201291065A1 (ru) Антитела против vla-4
EA201400447A1 (ru) АНТИТЕЛА К CD1d
WO2012047732A3 (en) Antibody compositions and methods of use
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
HK1198832A1 (en) Fn14 binding proteins and uses thereof
EP4269562A3 (en) Antigen binding molecules and methods of use thereof